Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema

PURPOSE: The aim of this study was to estimate the 1‐year costs associated with treating diabetic macular oedema (DME) patients using current intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) biologics compared with the dexamethasone implant. METHODS: We conducted a descriptive cost‐e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hertzberg, Silvia NW, Moe, Morten Carstens, Jørstad, Øystein Kalsnes, Petrovski, Beáta Éva, Burger, Emily, Petrovski, Goran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790387/
https://www.ncbi.nlm.nih.gov/pubmed/35467793
http://dx.doi.org/10.1111/aos.15151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790387/
https://www.ncbi.nlm.nih.gov/pubmed/35467793
http://dx.doi.org/10.1111/aos.15151

Ejemplares similares